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Introduction

In-vitro 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay
The MTT assay, first described by Mosmann, 15 was used to evaluate the in-vitro cytotoxicity by quantifying viable cells after antibody treatments (5 μ g/ml final concentration) for 4 days at 37°C
in the absence or presence of goat anti-human (GAH) IgG (20 μ g/ml final concentration).
Immunoblot analysis
Selected cell lines (1 X 10 7 cells) were treated with IMMU-114 (10 nM), rituximab (20 
Annexin-V binding assay
Cells were plated in six-well plates (2 x 10 5 cells per well) and pretreated with various inhibitors for 2 h. IMMU-114 (10 nM) was added to the wells, and incubation continued for 24 h. N-acetyl cystein (NAC, 5 mM) was used to block the reactive oxygen species (ROS). 16 
Inhibition of ERK and JNK pathways by siRNA analysis
The specific siRNAs for the ERK and JNK MAPK pathways were bought from Cell Signaling
Technology. Raji cells were transfected with either siERK, siJNK, or both siRNAs in the presence of transfection reagent DMRIE-C (Invitrogen) for 48 h, as described by the manufacturers. IMMU-114 (10 nM) was then added to the mixture and incubation continued for 
Assessment of mitochondrial depolarization (Δψ m ) and ROS production
Mitochondrial membrane potential depolarization was determined by using the fluorescent dye TMRE (Invitrogen), as described. 19 Briefly, Raji cells (2 x 10 5 cells per well) in six-well plates were treated with IMMU-114 for the indicated time points followed by incubation with TMRE (50 nM final concentration) for 30 min at 37 o C in the dark. Cells were washed three times with PBS and analyzed by flow cytometry. For ROS production, cells were incubated with the antibodies as for mitochondrial depolarization and stained with 2.5
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In vivo studies in SCID mice bearing disseminated MM tumors
For studies on the therapeutic effect of the mAbs, 6-8-week-old female SCID mice were used (Taconic Farms, Germantown, NY). Myeloma cells were injected via the tail vein. Treatments were initiated after injection of tumor cells according to dose schedules described below for each experiment. Mice were examined daily for signs of distress or hind-leg paralysis, and weighed weekly. Paralysis of the hind legs or a weight loss of >20% was used as the survival endpoint, when animals were euthanized. Animal studies were performed under protocols approved by the Center for Molecular Medicine and Immunology Institutional Animal Care and Use Committee.
Results
Reactivity and cytotoxicity of IMMU-114 on a panel of malignant B-cell lines and CLL patient specimens compared to other anti-B-cell mAbs
We demonstrated previously that IMMU-114 is expressed at markedly higher levels and is much more potent in vitro than other naked mAbs tested in NHL cell lines. 8 Expression of HLA-DR, CD74, CD22, and CD20 was compared on a panel of malignant B-cell leukemia, lymphoma and myeloma cell lines ( Peripheral blood samples were obtained from 6 representative CLL patients, who ranged in age from 62 to 83 years and had received either no prior treatment or the various therapies shown in Greater patient numbers will be needed to substantiate this trend. Cytotoxicity of anti-B-cell mAbs on 4 of the clinical CLL specimens was tested by incubating them with the mAbs, with and without second antibody crosslinking, for 2 days (Figure 2) . Approximately 60% inhibition (range 50.9±7.6%
to 61.9±8.6% inhibition relative to untreated cells) was obtained following incubation with IMMU-114, regardless of the presence or absence of second antibody. In contrast, neither rituximab nor veltuzumab yielded relevant inhibition. Significant milatuzumab inhibition was obtained in 3/4 specimens, and consistent with previous data on milatuzumab cytotoxicity, crosslinking was necessary for activity.
11
Effects of IMMU-114 on PBCs from healthy blood donors
The toxicity of IMMU-114 on normal PBCs was examined using an ex-vivo flow cytometry assay on whole blood from healthy volunteer donors. Data shown in Figure 3 Figure S1A . As shown in Table 4 and Figure S1B , these experiments confirmed that in unstimulated and PHA-stimulated blood, B-cell count decreases caused by IMMU-114 were 
Comparison of signaling pathways in IMMU-114-sensitive and -resistant cell lines and CLL patient specimens
Signaling pathways were studied to elucidate why cytotoxicity does not always correlate with antigen expression in the malignant B-cell lines examined in Tables 1 and 2 Consistent with the cytotoxicity data of Table 2 
IMMU-114 induces ROS production and changes in mitochondrial membrane potential
To further investigate the molecular mechanism whereby IMMU-114 induces cell death, we ROS has been reported to play a crucial role in caspase-independent apoptosis by rituximab. 22 We therefore investigated the effects of IMMU-114 on cleavage of caspases-3 and -9 in a time-dependent manner. We did not observe any change or cleavage of these caspases 
In vivo activity of IMMU-114 on tumor-bearing SCID mice
The therapeutic activity of IMMU-114 was evaluated in three NHL models, WSU-FSCCL, Namalwa, and Raji. IMMU-114 was more effective than the other anti-B-cell mAbs tested in all models. In the WSU-FSCCL study (Figure 6A ), where the mAbs were administered at 12.5 mg/kg (250 μg/injection) beginning the day following injection of tumor cells, IMMU-114 treatment yielded 100% long-term survival. Milatuzumab was also effective, yielding 7/10 long-term survivors.
Although the other anti-B-cell mAbs also induced significant responses compared to untreated mice, median survival times were markedly less, and no long-term survivors were seen. The dose of IMMU-114 was lowered to 1.75 mg/kg (35 μg/injection) in the Namalwa model, and compared to 25 mg/kg (500 μg/injection) doses of milatuzumab, epratuzumab, and veltuzumab. IMMU-114 yielded 4/6 long-term survivors in the Namalwa-bearing SCID mice, compared to none in the other Figure 6B ). Since Namalwa and WSU-FSCCL express relatively low levels of CD20, it was not surprising that veltuzumab and rituximab had relatively low activity. In the Raji model 
Discussion
The chimeric anti-CD20 mAb, rituximab, was approved by the U.S. Food and Drug For There have been reports of anti-HLA-DR inducing apoptosis directly 45 All are Zap70-positive and CD38-negative. For personal use only. on September 14, 2017. by guest www.bloodjournal.org From
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